Developmental Research Program

认识到发展研究基金是SPORE的一个组成部分，我们承诺大约 每年15万美元用于这些努力。这代表了前列腺孢子预算的重要部分， 反映了对前列腺癌创新转化研究发展的持续承诺。 发展研究计划（DRP）的重点是为研究者提供资源， 提交R 01资助申请或同等提案的初步数据。的调查人员 鼓励前列腺癌领域以外的学生通过校园公告申请， 通过与SPORE调查人员的个人互动。我们制定了一个逐步的提案征集， 利用NIH类型PHS 398格式的试点项目的审查过程，该格式已被简化， 该报告指出，研究提案的周转问题，并认识到这些项目可能没有多少初步数据。 自1995年以来，我们已投资390万美元在我们的DRP，资助共89名调查人员通过77个试点项目， 63个种子赠款和35个暑期学生项目。这些奖项导致了超过4000万美元的后续 SPORE和非SPORE同行评审的资金和超过136篇出版的手稿。在此期间， 赠款周期，我们资助了9个试点项目（每个5万美元），导致超过970万美元的后续同行评审 资助和22篇出版物。Elisabeth Heath博士（Karmanos癌症研究所，KCI）和Evan Keller博士（U- M）将担任DRP的联合董事。希思博士是韦恩州立大学的肿瘤学和医学教授 大学和前列腺癌研究KCI主任。她是国防部资助的 前列腺癌临床试验联盟，其中KCI是整体患者和少数患者招募的领先研究中心 在前列腺癌临床试验中。她指导了许多本科生，医学生，癌症 生物学研究生和初级教员，并将担任临床专家。凯勒博士是一名教授 泌尿外科和病理学，在UM，UM Rogel癌症中心泌尿肿瘤学项目的联合主任， 指导NIH资助的前列腺癌骨转移计划项目，并担任单一 细胞分析核心，并将担任基础科学专家。在本提案中，将共同支持DRP 由U-M和KCI。密歇根大学将提供5万美元的资金，以支付密歇根大学联合主任的工作。KCI将 捐款50，000美元，以支持KCI调查员的DRP或CEP奖励，以及支付以下费用的资金 KCI联合总监我们向国家癌症研究所申请剩下的5万美元。

Recognizing that developmental research funds are an integral part of the SPORE, we commit approximately $150,000 per year to these endeavors. This represents a significant portion of the Prostate SPORE budget and reflects the continued commitment to the development of innovative translational research in prostate cancer. The focus of the Developmental Research Program (DRP) is to provide investigators the resources to generate preliminary data for the submission of an R01 grant application or an equivalent proposal. Investigators from outside the field of prostate cancer are encouraged to apply through campus-wide announcements as well as through personal interactions with the SPORE investigators. We developed a stepwise proposal solicitation and review process for pilot projects utilizing an NIH-type PHS 398 format that has been streamlined for rapid turnaround of research proposals and which recognizes that these projects may have little preliminary data. Since 1995, we have invested $3.9 million in our DRP, funding a total of 89 investigators though 77 pilot projects, 63 seed grants and 35 summer student projects. These awards have led to over $40 million in subsequent SPORE and non-SPORE peer-reviewed funding and over 136 published manuscripts. During this current grant cycle, we funded 9 pilot projects ($50K each) that led to over $9.7 million in subsequent peer-reviewed grant funding and 22 publications. Drs. Elisabeth Heath (Karmanos Cancer Institute, KCI) and Evan Keller (U- M) will serve as Co-Directors for the DRP. Dr. Heath is a Professor of Oncology and Medicine, at Wayne State University and Director of Prostate Cancer Research KCI. She is the Principal Investigator of the DOD-funded Prostate Cancer Clinical Trials Consortium where KCI is the leading site for overall patient and minority accrual in prostate cancer clinical trials. She has mentored numerous undergraduate students, medical students, cancer biology graduate students, and junior faculty members and will serve as a clinical expert. Dr. Keller is a Professor of Urology and Pathology, at UM, Co-Director of the Urologic Oncology program of the UM Rogel Cancer Center, directs an NIH-funded Program Project on Prostate Cancer Bone Metastasis and is Co-Director of the Single Cell Analysis Core and will serve as basic science expert. In this proposal, the DRP will be jointly supported by U-M and KCI. U-M will contribute $50,000 plus funds to cover effort for the U-M Co-Director. KCI will contribute $50,000 to support either a DRP or CEP award for a KCI investigator as well as funds to cover the KCI Co-Director. We are requesting the remaining $50,000 from NCI.